Δnp63 expression is a protective factor of progression in clinical high grade T1 bladder cancer

Journal of Urology

Volumn 193, Issue 4, 2015, Pages 1144-1150

  Gaya, Josep M ^a,b,c   López Martínez, Juan M ^c   Karni Schmidt, Orit ^a   Bonal, Dennis M ^a   Algaba, Ferran ^c   Palou, Joan ^c   Villavicencio, Humberto ^c   Benson, Mitchell C ^b   Cordon Cardo, Carlos ^a,b   Castillo Martin, Mireia ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Columbia University ^*  (United States)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

biological markers; disease progression; human; prognosis; TP63 protein; urinary bladder neoplasms

Indexed keywords

BCG VACCINE; DELTA NP63 PROTEIN; PROTEIN P53; PROTEIN P63; TUMOR MARKER; UNCLASSIFIED DRUG; TP63 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CYSTECTOMY; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; LYMPH VESSEL METASTASIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TRANSURETHRAL RESECTION; BIOSYNTHESIS; BLADDER TUMOR; CHEMISTRY; DISEASE COURSE; EVALUATION STUDY; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; PROTECTION;

DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM GRADING; PROTECTIVE FACTORS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 84926406700     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2014.10.098     Document Type: Article

References (30)

1. R.J. Sylvester, A.P. van der Meijden, and W. Oosterlinck Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466
2. A.C. James, and J.L. Gore The costs of non-muscle invasive bladder cancer Urol Clin North Am 40 2013 261
3. F. Millan-Rodriguez, G. Chechile-Toniolo, and J. Salvador-Bayarri Primary superficial bladder cancer risk groups according to progression, mortality and recurrence J Urol 164 2000 680
4. J. Palou, R.J. Sylvester, and O. Rodriguez Faba Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin Eur Urol 62 2011 118
5. R.J. Sylvester, M.A. van der, and D.L. Lamm Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964
6. J. Huguet, J.M. Gaya, and S. Sabate Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy Actas Urol Esp 34 2010 63
7. C.L. Amling, J.B. Thrasher, and H.A. Frazier Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder J Urol 151 1994 31
8. V. Pansadoro, P. Emiliozzi, and F. de Paula Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience Urology 59 2002 227
9. A. Shabsigh, R. Korets, and K.C. Vora Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology Eur Urol 55 2009 164
10. L. Dyrskjot, K. Zieger, and F.X. Real Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study Clin Cancer Res 13 2007 3545
11. J. Palou, F. Algaba, and I. Vera Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guerin Eur Urol 56 2009 829
12. T.C. Zuiverloon, A.J. Nieuweboer, and H. Vekony Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review Eur Urol 61 2012 128
13. N. Fristrup, B.P. Ulhoi, and K. Birkenkamp-Demtroder Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer Am J Pathol 180 2012 1824
14. B.W. van Rhijn, L. Liu, and A.N. Vis Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer BJU Int 110 2012 1169
15. A. Yang, M. Kaghad, and Y. Wang p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities Mol Cell 2 1998 305
16. M. Olivier, M. Hollstein, and P. Hainaut TP53 mutations in human cancers: origins, consequences, and clinical use Cold Spring Harb Perspect Biol 2 2010 a001008
17. U.M. Moll, and N. Slade p63 and p73: roles in development and tumor formation Mol Cancer Res 2 2004 371
18. H. Fukushima, F. Koga, and S. Kawakami Loss of DeltaNp63alpha promotes invasion of urothelial carcinomas via N-cadherin/Src homology and collagen/extracellular signal-regulated kinase pathway Cancer Res 69 2009 9263
19. F. Koga, S. Kawakami, and J. Kumagai Impaired Delta Np63 expression associates with reduced beta-catenin and aggressive phenotypes of urothelial neoplasms Br J Cancer 88 2003 740
20. K. Hibi, B. Trink, and M. Patturajan AIS is an oncogene amplified in squamous cell carcinoma Proc Natl Acad Sci U S A 97 2000 5462
21. E. Comperat, P. Camparo, and R. Haus Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases Virchows Arch 448 2006 319
22. M.J. Urist, C.J. Di Como, and M.L. Lu Loss of p63 expression is associated with tumor progression in bladder cancer Am J Pathol 161 2002 1199
23. O. Karni-Schmidt, M. Castillo-Martin, and T.H. Shen Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression Am J Pathol 178 2011 1350
24. P.M. Grambsch, and T.M. Therneau Proportional hazards tests and diagnostics based on weighted residuals Biometrika 81 1994 515
25. N.E. Buckley, S.J. Conlon, and K. Jirstrom The DeltaNp63 proteins are key allies of BRCA1 in the prevention of basal-like breast cancer Cancer Res 71 2011 1933
26. P. Tucci, M. Agostini, and F. Grespi Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer Proc Natl Acad Sci U S A 109 2012 15312
27. R. Matsubara, S. Kawano, and T. Kiyosue Increased DeltaNp63 expression is predictive of malignant transformation in oral epithelial dysplasia and poor prognosis in oral squamous cell carcinoma Int J Oncol 39 2011 1391
28. Y. He, X. Wu, and W. Tang Impaired delta NP63 expression is associated with poor tumor development in transitional cell carcinoma of the bladder J Korean Med Sci 23 2008 825
29. M. Castillo-Martin, J. Domingo-Domenech, and O. Karni-Schmidt Molecular pathways of urothelial development and bladder tumorigenesis Urol Oncol 28 2010 401
30. A.Y. Jia, M. Castillo-Martin, and J. Domingo-Domenech A common MicroRNA signature consisting of miR-133a, miR-139-3p, and miR-142-3p clusters bladder carcinoma in situ with normal umbrella cells Am J Pathol 182 2013 1171